The FDA-approved mTOR inhibitors include Sirolimus for treating patients with lymphangioleiomyomatosis with gene mutations of the tuberous sclerosis complex 2 gene in RCC, and Everolimus for RCC, pancreatic, and breast cancers. This evidence concerns the gene MTOR and renal cell carcinoma.